← All trials
NCT04578886
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 23, 2020
- Primary completion
- Dec 15, 2021
- Completion date
- Dec 15, 2022
- First posted
- Oct 8, 2020
- Last posted
- Nov 25, 2020
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Alabama, BirminghamLead sponsor
- University of Alabama, BirminghamOverall official - principal investigator
- University of Alabama, BirminghamReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.